Paragon 28, Inc. (FNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Paragon 28, Inc. (NYSE:FNA – Get Free Report) has earned a consensus rating of “Hold” from the six ratings firms that are presently covering the company, Ratings reports. Four research analysts have ...

Fintel reports that on January 29, 2025, Needham downgraded their outlook for Paragon 28 (NYSE:FNA) from Buy to Hold. Analyst ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $13.4, a ...

NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Paragon 28, Inc. (NYSE:FNA) shares are trading higher premarket on Wednesday. On Tuesday, the company inked a deal to be ...

The FNA Group is proud to announce the acquisition of Kent Investment Corporation, a well-established leader in the ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in cash is fair to Paragon 28 ...

Endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNA) is currently performed on a routine basis at many endoscopic centers and it is evident that this procedure has a major impact ...